E-mail lunthesis@163.com Phone 0551-65179860-203

China's first patent granted for COVID-19 vaccine

Pub Date:2020-08-18 08:41 Source:Xinhua

China's first patent for a COVID-19 vaccine has been granted by the National Intellectual Property Administration.

The patent was jointly applied for by a research team with the Academy of Military Sciences and CanSino Biologics Inc., a Chinese high-tech biopharmaceutical company, said a report in People's Daily.

The team led by Chen Wei, a researcher at the Institute of Military Medicine under the academy, developed the recombinant COVID-19 vaccine, with the modified defective adenovirus as the vector.

In March, the vaccine became the first in China to be approved to enter clinical trials.

According to the patent abstract, the vaccine shows good immunogenicity in both mouse and guinea pig models and can induce strong cellular and humoral immune response in a short period of time. It can be produced quickly on a large scale to cope with a COVID-19 outbreak.

The vaccine has now finished phase-1 and phase-2 clinical trials, which have verified its safety and immunogenicity, said the report. Enditem


Related News
- Anhui fills first export order for gold    2020-08-17 10:51
- Chinese company sends staff back to Turkey for thermal po...    2020-08-11 08:49
- Two Anhui-based firms make debuts on NEEQ Select    2020-08-10 10:21
- Xuancheng sets up sci-tech innovation center in Shanghai    2020-08-06 11:11
photo  >>
Hefei Wildlife Park takes measures to help animals fend off summer heat
Huangshan starts salvaging components of centuries-old bridge
Video  >>
(AmazingAnhui)She inkstone, a national cultural heritage in E China's Anhui
(AmazingAnhui)Huizhou inkstick, a cultural heritage in E China's Anhui
People  >>
Chinese farmers take advantage of high tech to increase production
Flood relief soldiers leave messages for students
Travel  >>
China steps up flood control in Yangtze River
Rail network gets boost; more tracks to be high-speed
Contact Us
Copyright ©2000-2016 anhuinews.com All rights reserved. Reproduction in whole or in part without permission is prohibited.